Impact News +++ Sterling vs. MasTec: Which Infrastructure Stock is the Better Buy? (Zacks) +++ MASTEC Aktie +3,72%

PALVELLA Aktie

>PALVELLA Aktienkurs

105.5 EUR (TradegateBSX)

Ask: 106 EUR / 100 Stück

Bid: 105 EUR / 100 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PALVELLA Aktie über LYNX handeln

Intraday

1 Jahr

>PALVELLA Performance

1 Woche: +8,0%

1 Monat: +4,5%

3 Monate: -0,8%

6 Monate: +26,8%

1 Jahr: +354,9%

laufendes Jahr: +14,2%

>PALVELLA Aktie

Name:

PALVELLA THERAPEUTICS NEW

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6979471090 / A40RA6

Symbol/ Ticker:

PI6 (Frankfurt) / PVLA (NASDAQ)

Kürzel:

FRA:PI6, ETR:PI6, PI6:GR, NASDAQ:PVLA

Index:

Webseite:

https://palvellatx.com/

Profil:

Palvella Therapeutics Inc is a pharmaceutical company committed to the development of therapies for rare and serious dermatologic conditions. Its primary focus lies in creating innovative treatments that address unmet medical needs in the dermatology..
>Volltext..

Marktkapitalisierung:

1414.1 Mio. EUR

Unternehmenswert:

1187.73 Mio. EUR

Umsatz:

EBITDA:

Nettogewinn:

-42.97 Mio. EUR

Gewinn je Aktie:

-3.63 EUR

Schulden:

Liquide Mittel:

179.92 Mio. EUR

Operativer Cashflow:

Bargeldquote:

28.73

Umsatzwachstum:

-100%

Gewinnwachstum:

-183.28%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

PALVELLA

Letzte Datenerhebung:

22.06.26

>PALVELLA Kennzahlen

Aktien/ Unternehmen:

Aktien: 14.34 Mio. St.

Frei handelbar: 70.61%

Leerverk. Aktien: 14.77%

Rückkaufquote: -

Mitarbeiter: 29

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 98%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 7.83

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -28.73%

Eigenkaprendite: -34.25%

>PALVELLA Peer Group

Gesundheit, Hauterkrankungen & -behandlung/ Dermatologie, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>PALVELLA Chart & Kurs - NASDAQ

>PALVELLA News

22.06.26 - 16:24	Palvella Therapeutics: Aktie nach positiven FDA- und Patent-Nachrichten auf dem Vormarsch (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.06.26 - 14:18	FDA gewährt rollierendes Prüfverfahren für Palvella Medikament – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.06.26 - 13:33	FDA Grants Rolling Review of Palvella′s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations (GlobeNewswire EN)
	FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted...

03.06.26 - 13:33	Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations (GlobeNewswire EN)
	Palvella remains on track to submit an NDA in the second half of 2026...

02.06.26 - 13:33

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire EN)

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET....

27.05.26 - 13:33	Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 (GlobeNewswire EN)
	Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP)...

23.05.26 - 01:01	Insiderhandel: Chief Operating Officer verkauft Aktien von Palvella Therapeutics im Wert von 475631 USD (Insiderkauf)
	Goin, Kathleen - Vorstand - Tag der Transaktion: 2026-05-20...

21.05.26 - 13:36

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards (GlobeNewswire EN)

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been named the Healthcare & Life Sciences Company of the Year at the 2026 Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards....

20.05.26 - 22:33	Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malf (GlobeNewswire EN)
	In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) scale at Week 24, with a mean improvement of +2.46 (p...

15.05.26 - 13:33	Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire EN)
	100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) at Week 12 (+2.5 point improvement; p=0.003)...

13.05.26 - 14:21	Palvella Therapeutics approved for transfer to Nasdaq Global Market (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 13:33	Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market (GlobeNewswire EN)
	Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations...

08.05.26 - 06:36	Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.26 - 20:36	Earnings Call Transkript: Palvella-Aktie bricht trotz starker Liquiditätsposition nach Q1 2026 ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.26 - 13:33	Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026...

04.05.26 - 13:33	Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas (GlobeNewswire EN)
	Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S....

30.04.26 - 13:33

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 (GlobeNewswire EN)

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update....

20.04.26 - 13:33	Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 (GlobeNewswire EN)
	James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET...

18.04.26 - 00:01	Insiderhandel: Chief Operating Officer verkauft Aktien von Palvella Therapeutics im Wert von 547399 USD (Insiderkauf)
	Goin, Kathleen - Vorstand - Tag der Transaktion: 2026-04-15...

13.04.26 - 13:33	Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors (GlobeNewswire EN)
	Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Keine Blume blüht hundert Tage lang, und niemand ist tausend Tage lang gut. - Sprichwort China

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram